Patient Satisfaction and Quality of Life Impact - PecFent®

A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01693328

Acronym

Qualipec

Enrollment

300

Registered

2012-09-26

Start date

2012-09-30

Completion date

Unknown

Last updated

2014-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breakthrough Cancer Pain

Keywords

quality of life, PecFent, Lazanda, fentanyl, intranasal, breakthrough cancer pain

Brief summary

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions. • Study objectives include assessment of early treatment satisfaction.

Interventions

DRUGPecFent® (fentanyl) nasal spray

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult (aged ≥18 years) with cancer * Taking at least 60 mg of oral morphine sulfate or equivalent per day for chronic background pain

Design outcomes

Primary

Measure	Time frame	Description
Satisfaction	Satisfaction will be assessed approximately 1 hour after each BTPc episode treated with PecFent® from completion of titration through Day 7	Satisfaction will be assessed using a 4-point Likert scale.

Countries

France

Contacts

Primary ContactSylvie Allouche, MD

sylvieallouchecovarrubias@archimedespharma.com+33155702320

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026